StockWatch
·

PUNJAB CHEMICALS AND CROP PROTECTION LTD.-$ Q1 FY27 Results

PUNJABCHEMQ1 FY27 Results
Filing
Result:Steady· Market: CrashedMargin expansion
MetricValueQ4 FY26Q1 FY26
Revenue347.24 Cr66.5%8.7%
Total Income347.92 Cr65.0%7.6%
Expenditure317.86 Cr63.2%7.5%
PBT30.06 Cr86.1%8.9%
Net Profit22.07 Cr101.0%7.0%
OPM11.75%1.45pp1.00pp
NPM6.34%1.13pp0.04pp
EPS18.00100.9%7.0%
View full financials

Revenue/PAT growth of 8.7%/7% YoY is modest and well short of management's own 15-20% guidance, with operating margin expansion offset by a higher tax rate leaving net margin flat — an in-line, unexceptional quarter for the sector.

Q1 FY-2027 RESULTS · PUNJABCHEM

Punjab Chemicals: consolidated PAT +7% YoY to ₹22 Cr as growth trails FY27 guide

PAT +6.98% YoY · revenue +8.68% · margins expanding

31 Jul 2026 · 3 min read
Revenue

₹347.24 Cr

+8.68% YoY

PAT (consolidated)

₹22.07 Cr

+6.98% YoY

Net margin

6.34%

0pp YoY

EPS

₹18

Punjab Chemicals reported consolidated revenue of ₹347.24 Cr for Q1 FY27, up 8.7% YoY from ₹319.51 Cr in Q1 FY26 and up 66.5% QoQ from ₹208.56 Cr in Q4 FY26 — the large QoQ jump reflects a seasonally weak March-quarter base (which included a sharp inventory drawdown) rather than genuine sequential acceleration, and should not be read as momentum. Consolidated PAT was ₹22.07 Cr, up 7.0% YoY from ₹20.63 Cr, with EPS of ₹18.00 versus ₹16.83 a year ago. Standalone PAT of ₹22.15 Cr was nearly identical to the consolidated number, so the two bases tell the same story this quarter.

The scoreboard

Q1 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q1 FY-2027QoQYoY
Revenue₹347.24 Cr+66.5%+8.7%
Expenses₹317.86 Cr+63.2%+7.5%
PAT₹22.07 Cr+100.98%+6.98%
Net margin6.34%+1.1pp0pp
EPS₹18+100.9%+7%

Margins improved at the operating line — OPM expanded to roughly 11.75% from about 10.75% a year ago — but net margin was flat at 6.36% versus 6.38%, as the effective tax rate rose to about 26.6% from 25.3%, absorbing the operating gains before they reached the bottom line. With no exceptional items in either period, reported and adjusted growth are identical: 8.7% revenue and 7.0% PAT YoY, with nothing to normalize for.

886.96975.161,063.351,151.541,239.741,19204-2705-2006-1507-0907-31Q1 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹1,192, up 7% over the past month of trading.

₹ Cr
08.2416.4824.727.05Q4 FY25rev ₹202 Cr20.63Q1 FY26rev ₹320 Cr18.54Q2 FY26rev ₹255 Cr13.81Q3 FY26rev ₹247 Cr10.98Q4 FY26rev ₹209 Cr22.07Q1 FY27rev ₹347 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 6 quarters on our records; revenue is at a 6-quarter high.

What management guided (4 FY-2026 call)
Management reaffirms its revenue growth guidance of 15-20% for FY27, driven by strong performance from new products and stable demand for existing molecules. They are targeting a gradual improvement in EBITDA margins from the current ~12% level towards 15% over the next two to three years, supported by a richer product

This quarter: missed

The print lags management's own guidance: at the Q4 FY26 concall, management reaffirmed a target of 15-20% revenue growth for FY27 and a gradual EBITDA margin improvement from ~12% toward 15% over two to three years. Q1's 8.7% YoY revenue growth is well short of that band, though the ~11.75% operating margin is broadly consistent with the ~12% starting point management cited. No analyst consensus or brokerage preview specific to this quarter could be located — coverage of the stock appears thin — so street expectations are not assessed here. No standalone management press release or commentary accompanied this filing beyond the board-outcome letter, so there is no separate management framing to cross-check against the numbers.

  • W1

    FY27 revenue growth needs to run well above Q1's 8.7% YoY pace in the remaining quarters to hit management's reaffirmed 15-20% full-year guidance.

  • W2

    Effective tax rate rose to ~26.6% from ~25.3% YoY this quarter — watch whether it normalizes or keeps offsetting OPM expansion at the NPM line.

  • W3

    Commercialization of the three MoU products flagged for FY27 and progress on securing a Greenfield CAPEX site — both cited as FY27 priorities but not yet visible in this quarter's numbers.

No exceptional items in the current or year-ago quarter (the ₹208 Lakh New Labour Codes charge sits only in the FY26 full-year column, not any quarterly column), so no adjustment is needed for YoY comparisons; standalone and consolidated PAT diverge by under 1% this quarter.

Informational and educational content only. Not investment advice.

PUNJAB CHEMICALS AND CROP PROTECTION LTD.-$ (PUNJABCHEM) Q1 FY27 Results — StockWatch